SCHEMBL8499750

SCHEMBL8499750

CCCC1O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 8/20 0.74
▸ CYP3A4 P08684 6/20 0.74
▸ PGR P06401 5/20 0.74
▸ HIF1A Q16665 4/20 0.74
▸ ABCB11 O95342 4/20 0.74
▸ AR P10275 3/20 0.74
▸ HSD17B10 Q99714 2/20 0.74
▸ LMNA P02545 2/20 0.74
▸ SMN1; SMN2 Q16637 2/20 0.74
▸ NPSR1 Q6W5P4 2/20 0.74
▸ ABCC3 O15438 1/20 0.74
▸ ABCC4 O15439 1/20 0.74
▸ IL5 P05113 1/20 0.74
▸ NR3C2 P08235 1/20 0.74
▸ CHRM1 P11229 1/20 0.74
▸ MMP9 P14780 1/20 0.74
▸ NFKB1 P19838 1/20 0.74
▸ THPO P40225 1/20 0.74
▸ BLM P54132 1/20 0.74
▸ PMP22 Q01453 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29666990 0.94 NR3C1 (0.76) NR3C1CYP3A4PGRHIF1AABCB11
Flunisolide SCHEMBL2393174 0.89 NR3C1 (0.79) NR3C1CYP3A4PGRHIF1AABCB11
SCHEMBL20149521 0.87 PGR (0.57) NR3C1CYP3A4PGRHIF1AABCB11
SCHEMBL8501938 0.87 CYP3A4 (0.57) NR3C1CYP3A4PGRHIF1AABCB11
SCHEMBL20149149 0.87 PGR (0.57) NR3C1CYP3A4PGRHIF1AABCB11
SCHEMBL24591950 0.85 CYP3A4 (0.56) NR3C1CYP3A4PGRHIF1AABCB11
SCHEMBL21153554 0.85 CYP3A4 (0.56) NR3C1CYP3A4PGRHIF1AABCB11
SCHEMBL21569953 0.85 NR3C1 (0.56) NR3C1CYP3A4PGRHIF1AABCB11
SCHEMBL21152861 0.85 CYP3A4 (0.56) NR3C1CYP3A4PGRHIF1AABCB11
Budesonide SCHEMBL13695912 0.85 NR3C1 (1.00) NR3C1CYP3A4PGRHIF1AABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11377502-B2 Anti-MSR1 antibodies and methods of use thereof REGENERON PHARMACEUTICALS, INC. (US) 2022-07-05 — — US disclosed
US-5888995-A ANTIINFLAMMATORY AND ANTIALLERGENIC AGENTS; A NOVEL GLUCOCORTICOSTEROID ASTRA AKTIEBOLAG (SE) 1999-03-30 — — US disclosed
US-5614514-A Steroid esters AKTIEBOLAGET ASTRA (SE) 1997-03-25 — — US disclosed
US-4695625-A Process for the preparation of 16,17 acetals of pregnane derivatives SICOR SOCIETA ITALIANA CORTICOSTEROIDI S.P.A. (IT) 1987-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11377502-B2 Anti-MSR1 antibodies and methods of use thereof CD47, MSR1, LDLR NR3C1 1628/4885CYP3A4 4497/4885PGR 3140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback